CLDX

Celldex Therapeutics, Inc.

A clinical-stage biotechnology company that makes antibody-based medicines designed to calm overactive immune responses behind inflammatory, allergic, and autoimmune conditions. Its lead drug candidate, barzolvolimab, targets a receptor on mast cells to treat chronic hives and other mast-cell-driven diseases. The company was born in 2008 when AVANT Immunotherapeutics merged with a private firm, and its name blends "cell" with the pharma-style "-dex" suffix.